Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy

Liver International

Volumn 27, Issue 10, 2007, Pages 1349-1355

  Yen, Yi Hao ^a   Lu, Sheng Nan ^a   Chen, Chien Hung ^a,b   Wang, Jing Houng ^a   Wu, Chun Mei ^a   Hung, Chao Hung ^a   Tseng, Po Lin ^a   Hu, Tsung Hui ^a   Changchien, Chi Sin ^a   Lee, Chuan Mo ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Biochemical breakthrough; HBV DNA; HepatitisB e antigen; Lamivudine; Tyrosine methionine aspartate aspartate (YMDD) mutant; Virological breakthrough

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT DURATION; VIROLOGY; VIRUS MUTATION;

ADULT; ALANINE TRANSAMINASE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 36349024736     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01609.x     Document Type: Article

References (34)

1. Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993; 262: 369-70.
2. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 1997; 12: S218-22.
3. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86: 1143-50.
4. Liaw YF, Leung N, Guan R, Lau GK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 2003; 18: 239-45.
5. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
6. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
7. Lai CL, Chein RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
8. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
9. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-7.
10. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
11. Lee CM, Ong GY, Lu SN, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002; 37: 669-74.
12. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
13. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
14. Chen CH, Lee CM, Lu SN, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004; 41: 454-61.
15. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002; 37: 366-9.
16. Chen CH, Wang JH, Lee CM, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11: 771-8.
17. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
18. Liaw YF. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology 2007; 45: 266-8.
19. Lok AS, Zoulim F. Hepatitis B Virus Drug Resistance Working Group et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 4: 254-65.
20. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
21. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
22. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
23. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: A comparison with HBV DNA testing. Hepatology 1993; 18: 1306-12.
24. Park NH, Shin JW, Park JH, et al. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg-positive chronic hepatitis B. J Viral Hepat 2005; 12: 216-21.
25. Shin JW, Park NH, Jung SW, et al. Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol 2006; 12: 6693-8.
26. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-93.
27. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis 2003; 23: 69-80.
28. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 2005; 43: 72-7.
29. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25: 1097-107.
30. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
31. Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38: 315-21.
32. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 2005; 12: 398-404.
33. Tsubota A, Arase Y, Suzuki F, et al. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol 2004; 73: 7-12.
34. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.